A clinical, evidence-graded monograph for every peptide.
The Peptide Encyclopedia is our A-Z reference of individual peptide monographs. Each entry covers what a peptide is, how it works, the strength of the human and preclinical evidence behind it (graded A-D), the doses and routes reported in the literature, its documented risks, and its current FDA and anti-doping status — every claim tied to a real, verifiable source. It is the reference spine of the site, written for readers who want the clinical record rather than the hype.
A clinical monograph on calcitonin salmon — the FDA-approved antiresorptive bone hormone with Grade A human-trial support for modest effects in a narrowing niche: acute hypercalcemia, Paget's disease, and short-term osteoporotic-fracture analgesia.
A clinical monograph on cagrilintide — the long-acting amylin analogue and amylin half of CagriSema. Genuine phase 3 human RCTs, ~22.7% combination weight loss, and an unapproved 2026 legal status.
Peptide EncyclopediaA clinical monograph on Actovegin — the deproteinized calf-blood hemodialysate marketed abroad for diabetic neuropathy, post-stroke cognition and sports recovery. Two human RCTs, an ill-defined composition, and an unapproved U.S. status.
Peptide EncyclopediaA clinical monograph on Bronchogen — the lung/bronchial 'bioregulator' tetrapeptide (ADEL/AEDL) from the Khavinson short-peptide program. Promising preclinical biology, zero human efficacy or safety trials, and an unapproved 2026 legal status.
Peptide EncyclopediaA clinical monograph on the arginate (di-L-arginine) salt of BPC-157 — the same peptide with an arginine counterion. The storage and gastric-acid stability advantage is real; the headline oral-bioavailability claims are unproven marketing.
Peptide EncyclopediaA clinical monograph on Argireline — the 'topical Botox' peptide. Modest human evidence (Grade B), a real SNAP-25 mechanism, and a delivery problem that undercuts the marketing.
Peptide EncyclopediaA clinical monograph on ARA-290 (cibinetide) — the non-erythropoietic EPO-derived peptide with genuine Phase 2 RCT data for small-fiber neuropathy, no Phase 3, and an unapproved, WADA-prohibited 2026 status.
Peptide EncyclopediaA clinical monograph on Angiotensin-(1-7) / TXA127 (talfirastide) — the effector of the protective ACE2/Mas arm of the renin-angiotensin system. Real human RCTs, a negative COVID-19 trial, and no FDA approval.
Peptide EncyclopediaA clinical monograph on alanyl-glutamine (Dipeptiven) — the stable dipeptide built to deliver glutamine intravenously. Grade-A but contested evidence in parenteral nutrition, with a major high-dose mortality signal.
Peptide EncyclopediaA clinical monograph on abaloparatide (Tymlos) — the FDA-approved PTHrP(1-34) bone-anabolic peptide. Phase 3 RCT fracture data in women and men, RG-selective PTH1R mechanism, and 2026 regulatory status.
Peptide EncyclopediaA clinical monograph on AOD-9604 — the hGH-fragment fat-loss peptide that completed six human RCTs and largely failed to beat placebo. Strong safety data, a failed pivotal weight-loss trial, and an unsettled 2026 legal status.
Peptide EncyclopediaA clinical monograph on adipotide (FTPP) — the fat-targeted proapoptotic peptide that shrinks white fat by ablating its blood supply. Dramatic preclinical fat loss, no completed human trial, and a documented kidney-toxicity signal.
Peptide EncyclopediaA clinical monograph on 5-Amino-1MQ — the small-molecule NNMT inhibitor sold as a fat-loss and longevity 'peptide.' Despite its peptide-channel marketing, it is not a peptide, and every efficacy finding is preclinical.
Peptide EncyclopediaA clinical monograph on BPC-157 — the stable gastric pentadecapeptide marketed for tendon, gut and wound healing. Deep preclinical data, no completed human RCT, and an unsettled 2026 legal status.
A peptide monograph is a single, structured reference page for one peptide. On PeptideVox each monograph covers identity and chemistry, mechanism of action, the indication-by-indication evidence (each graded A-D), reported dosing and routes from the literature, safety and contraindications, and current legal and anti-doping status. Every efficacy claim carries an evidence grade and an inline citation to a real study, regulatory document, or trial registry so you can check the source yourself. The format is informational and editorial — it is not medical advice.
PeptideVox grades every efficacy claim on an A-D scale. Grade A means human randomized controlled trials or meta-analyses support the claim; grade B means lower-tier human evidence such as cohort or open-label studies; grade C means preclinical only (animal or in-vitro) with no qualifying human efficacy data; and grade D means anecdotal, mechanistic-only or marketing claims with no controlled evidence. Grading is deliberately conservative — preclinical promise never earns an A or B, and the grade always reflects the human-evidence level when human and animal data conflict.
No. The encyclopedia is strictly informational and editorial. It does not recommend vendors, link to sellers of unapproved peptides, or tell you how to source or self-administer anything. Dosing figures are reported only as they appear in the published literature and clinical or anecdotal use, for completeness — never as a protocol to follow. Many peptides covered here are not FDA-approved, are sold as "research chemicals not for human use," and may be prohibited in sport. Always consult a licensed clinician before any health decision.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
